Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. USO
7. AMD
8. AMC
9. META
10. NUAI

Go back to Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
(NASDAQ: AUTL) Delayed: 1.94 --0 (-0%)
Previous Close $1.94    52 Week High $ 
Open $1.95    52 Week Low $ 
Day High $1.96    P/E N/A 
Day Low $1.91    EPS $ 
Volume 514,192